(BMY - Get Report)
stood by its bid for
this week, in the process raising a point of contention between the two companies that will be key to any potential buyer.
The pharmaceutical company and ImClone openly disagree on who owns the rights to a next-generation version of cancer drug Erbitux -- which will pose a significant threat to their shared product.
Greg Mayes, ImClone's vice president and interim general counsel said in the company's second-quarter conference call that ImClone believes it fully owns the IMC-11F8 molecule.
Bristol, which has marketing rights to Erbitux in the U.S., said in its most recent letter to ImClone's board that it also has U.S. rights to IMC-11F8 and other Erbitux-related products.
In a retort Thursday night, ImClone's chairman and activist investor Carl Icahn jabbed: "With regard to your assertion concerning rights to IMC-11F8 (which, if ultimately approved for sale, may have a significant competitive effect on ERBITUX), we disagree that Bristol's rights are clear and do not waive any rights that we may have with regard thereto."
IMC-11F8 is a fully humanized version of Erbitux, meaning it won't cause the severe allergic reactions that occur in some patients who take Erbitux,
Senior Columnist Adam Feuerstein wrote on sister site
(RealMoney.com subscription required) earlier this week. Theoretically, it should also be as effective, and thus could potentially overtake the Erbitux franchise.
Exactly what belongs to whom in the Bristol-ImClone partnership will be a key question of interest as
ImClone's new mystery bidder
conducts its due diligence over the next few weeks.
Earlier in the week, ImClone announced that it had received an offer from a large unnamed pharmaceutical company that trumps Bristol's $60 a share bid by $10 a share. Subsequently, ImClone's board officially deemed the Bristol proposal as inadequate.